Literature DB >> 14994369

Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA).

Luis Escribano1, Beatriz Diaz-Agustin, Antonio López, Rosa Núñez López, Andrés García-Montero, Julia Almeida, Aranzazu Prados, Miguel Angulo, Sonia Herrero, Alberto Orfao.   

Abstract

BACKGROUND: Mastocytosis is a term used for a heterogeneous group of disorders characterized by an abnormal proliferation and accumulation of mast cells (MCs) in one or multiple tissues including skin, bone marrow, liver, spleen, and lymph nodes, among others.
METHODS: In recent years, multiparameter flow cytometric studies have shown that pathologic MCs from patients with mastocytosis display unique aberrant immunophenotypic characteristics as compared with normal MCs.
RESULTS: Among other features, pathologic MCs show aberrant expression of CD25 and CD2 antigens and abnormally high levels of the CD11c and CD35 complement receptors, the CD59 complement regulatory molecule, the CD63 lysosomal membrane antigen, and the CD69 early-activation antigen. In addition, MCs from mastocytosis express abnormally low levels of CD117 and unexpectedly high light scatter and autofluorescence characteristics.
CONCLUSIONS: These aberrant immunophenotypic features are of great relevance for the assessment of tissue involvement in mastocytosis with consequences in the diagnosis, classification, and follow-up of the disease and in its differential diagnosis with other entities. In this paper we provide the reader with information for the objective and reproducible identification of pathologic MCs by using quantitative multiparametric flow cytometry, information for their phenotypic characterization, and the criteria currently used for a correct interpretation of the immunophenotypic results obtained. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14994369     DOI: 10.1002/cyto.b.10072

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  22 in total

Review 1.  Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment.

Authors:  Cem Akin; Peter Valent; Luis Escribano
Journal:  Curr Allergy Asthma Rep       Date:  2006-07       Impact factor: 4.806

2.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

3.  High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.

Authors:  Robert Fritsche-Polanz; Marika Fritz; Andrea Huber; Karl Sotlar; Wolfgang R Sperr; Christine Mannhalter; Manuela Födinger; Peter Valent
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

4.  Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay.

Authors:  Thomas Kristensen; Hanne Vestergaard; Michael Boe Møller
Journal:  J Mol Diagn       Date:  2011-03       Impact factor: 5.568

5.  A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.

Authors:  Jason Gotlib; John H Baird; Tracy I George; Cheryl Langford; Isabel Reyes; Justin Abuel; Cecelia Perkins; Kurt Schroeder; Prithviraj Bose; Srdan Verstovsek
Journal:  Blood Adv       Date:  2019-08-13

Review 6.  Anaphylaxis as a clinical manifestation of clonal mast cell disorders.

Authors:  A Matito; I Alvarez-Twose; J M Morgado; L Sánchez-Muñoz; A Orfao; L Escribano
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

Review 7.  Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  Cem Akin
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

Review 8.  Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected Association.

Authors:  Patrizia Bonadonna; Massimiliano Bonifacio; Carla Lombardo; Roberta Zanotti
Journal:  Curr Allergy Asthma Rep       Date:  2015-08       Impact factor: 4.806

9.  International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.

Authors:  Jason Gotlib; Animesh Pardanani; Cem Akin; Andreas Reiter; Tracy George; Olivier Hermine; Hanneke Kluin-Nelemans; Karin Hartmann; Wolfgang R Sperr; Knut Brockow; Lawrence B Schwartz; Alberto Orfao; Daniel J Deangelo; Michel Arock; Karl Sotlar; Hans-Peter Horny; Dean D Metcalfe; Luis Escribano; Srdan Verstovsek; Ayalew Tefferi; Peter Valent
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

Review 10.  Immunology and clinical manifestations of non-clonal mast cell activation syndrome.

Authors:  Juan-Carlos Cardet; Mariana C Castells; Matthew J Hamilton
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.